Access
Pharmaceuticals
MuGard’s Effective Treatment of Mucositis
(OTCBB: ACCP)
2600 Stemmons
Freeway, Suite 176
Dallas, TX 75207-2107
Tel: (214) 905-5100 Public Relations Contact:
Fax: (214) 905-5101 ProActive Capital Group
50 Broad Street, Suite 1437
New York, NY 10004
USA
EMAIL: info@Pro-ActiveCapital.com
PHONE: (646) 315-7070
FAX: (646) 315-7080
Presentation by:
Tom Allinder
Director, Investor Relations 2.0 for ProActive Capital

MuGard’s Effective Treatment of Mucositis
Mucositis is the painful inflammation and ulceration of the mucous
membranes lining the digestive tract, usually as an adverse effect of
chemotherapy and radiotherapy treatment for cancer…
MuGard is a an oral rinse which provides a protective coating to the
mucus membranes inside the mouth and digestive tract…
 In a comparison of patients undergoing standard care with patients
using MuGard, the incidence and severity of mucositis was significantly
lower for the MuGard group.
MuGard has received marketing allowance in the United States
under a 510(k) from the Food and Drug Administration.

MuGard’s Effective Treatment of Mucositis
MuGard™ is formulated to provide a long-lasting yet unobtrusive
protective coating of the oral membranes.
Access Pharma conducted a 56-patient multi-
center, randomized, double-blind clinical study in patients undergoing
radiation therapy for head and neck cancer
Subjects treated with the MuGard™ Oral Rinse had less severe
mucositis when compared to 44 patients who received no specific
therapy for the prevention of mucositis (Sonis et al, Cancer, 2000, 89:
2103).
The beneficial effects of MuGard™ Oral Rinse were further confirmed
when they were compared to another previously published set of 18
historical controls (Epstein et al, Cancer, 2000, 89: 2258).

MuGard’s Effective Treatment of Mucositis
Access Pharma concluded
that MuGard™ Oral Rinse
shows substantial promise
for reducing the severity of
radiation-induced mucositis.

MuGard’s Effective Treatment of Mucositis
Mucositis and infections in the mouth remain
major complications…
These complications continue despite the usual
oral care provided for patients with cancer such
as frequent mouth cleansing, rinsing with
buffered saline and fluoride solutions, and
administration of topical and systemic
antimicrobial agents.

MuGard’s Effective Treatment of Mucositis
Key Term: Oral Mucositis Assessment
Scale (OMAS)
 OMAS is a scale developed in 1999.
 The OMAS provides an objective assessment of
oral mucositis based on assessment of the
appearance and extent of redness and ulceration in
various areas of the mouth.
OMAS is computed as the sum of all the individual
erythema and ulceration scores, divided by the
number of anatomical sites graded

MuGard’s Effective Treatment of Mucositis
Clinical Results of patients treated with
amlexanox rinse vs MuGard:

MuGard’s Effective Treatment of Mucositis
“Standard Care” vs MuGard

MuGard’s Effective Treatment of Mucositis
Same Testing (“standard care”), different
center (Annova)

MuGard’s Effective Treatment of Mucositis
When analyzed for mucositis severity
(histogram, below), only 7% of patients never exceeded
an OMAS score of 0.5 in the control groups, compared
with 42% in the MuGard™ group (p = .0001).

MuGard’s Effective Treatment of Mucositis
Conclusions
The anti-allergic, anti-inflammatory drug amlexanox, appears to be
ineffective in either preventing, reducing the severity, or accelerating the
healing of mucositis.
Recognizing the limitations of a retrospective analysis of historical
databases, it appears that significant patient benefit is achieved when patients
utilize MuGard™.
Compared with patients on standard care, patients using MuGard™ had
delayed onset of mucositis and reduced severity, as assessed by the OMAS
scoring system.
Of particular note was that 43% of patients on MuGard™
experienced no mucositis (OMAS score never exceeded 0.5) compared with
only 7% in the control group.
These results indicate that MuGard™ could be highly effective in the
prevention and treatment of mucositis.

For More Information on MuGard and Access
Pharmaceuticals other Products please see:
http://www.accesspharma.com
Public Relations Contact:
ProActive Capital Group
50 Broad Street, Suite 1437
New York, NY 10004
USA
EMAIL: info@Pro-ActiveCapital.com
PHONE: (646) 315-7070
FAX: (646) 315-7080